Serendipity Biopharma files Form 144 to sell 25,000 shares

Serendipity Biopharma LLC files a Form 144 reporting proposed sales of Common Stock.

Rhea-AI Filing Summary

Serendipity Biopharma LLC files a Form 144 reporting proposed sales of Common Stock. The filing lists a proposed sale of 25,000 shares through Morgan Stanley Smith Barney LLC and discloses 66,610 shares sold during the prior three months. Transaction dates include 11/18/2020 and 01/12/2026.

Insights

Securities Compliance Counsel

Routine Form 144 notice of proposed resale by an affiliate with prior recent sales disclosed.

The filing lists a proposed resale of 25,000 shares via Morgan Stanley Smith Barney LLC and reports 66,610 shares sold on 01/12/2026. Form 144 is a notice used when restricted or control securities are to be sold.

Cash‑flow treatment and any holding‑period details are not stated in the excerpt; subsequent broker reporting and transaction settlement will provide final execution detail.

Key Figures

Proposed resale: 25,000 shares Prior sales (3 months): 66,610 shares Value reported (prior sales): $2,493,212.30 +2 more

5 metrics

Proposed resale 25,000 shares proposed sale via Morgan Stanley Smith Barney LLC

Prior sales (3 months) 66,610 shares sold on 01/12/2026

Value reported (prior sales) $2,493,212.30 aggregate value for 66,610 shares (01/12/2026)

Value shown (proposed broker line) $954,750.00 associated numeric field in broker line

Date referenced 04/09/2026 date appearing in filing header

Key Terms

Form 144, Proposed resale, Issuer

3 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Proposed resale financial

"Securities To Be Sold | Common | 25000"

Issuer legal

"Merger or Acquisition | Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Serendipity Biopharma's Form 144 (LQDA) disclose?

It discloses a proposed resale of 25,000 shares through Morgan Stanley Smith Barney and prior sales of 66,610 shares on 01/12/2026. The form notifies the SEC of an intended sale of restricted or control securities.

Who is the broker handling the proposed sale in the Form 144 for LQDA?

The filing names Morgan Stanley Smith Barney LLC at 1 New York Plaza as the broker-dealer. The excerpt shows the broker linked to the 25,000 share proposed transaction dated 11/18/2020.

How many shares were reported sold in the past three months in the Form 144 for LQDA?

The filing reports 66,610 shares sold during the prior three months, with a disclosed aggregate value of $2,493,212.30. The sale date shown is 01/12/2026.

Does the Form 144 state proceeds or who receives the sale proceeds for LQDA?

The excerpt does not state the recipient of proceeds or the use of proceeds. Form 144 typically notifies of intended sale; specific proceeds allocation is not included in the provided lines.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/09/2026 - 04:22 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001231615
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	LIQUIDIA CORPORATION
SEC File Number	001-39724
Address of Issuer	419 Davis Drive, Suite 100 Morrisville NORTH CAROLINA 27560
Phone	9193284400
Name of Person for Whose Account the Securities are To Be Sold	SERENDIPITY BIOPHARMA LLC
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25000	954750.00	88114429	04/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/18/2020	Merger or Acquisition	Issuer			25000	11/18/2020	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100 Morrisville NC 27560	Common	01/12/2026	66610	2493212.30

144: Remarks and Signature

Remarks
Date of Notice	04/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/05/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Roger Jeffs
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)